Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Mecamylamine Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

The Nicotinic Cholinergic System and Cognitive Aging

NCT03408574
View directory record Official record
Conditions
Healthy Aging
Interventions
Nicotine patch, oral mecamylamine, placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 4, 2026, 4:02 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Treatment of Orthostatic Intolerance

NCT00262470
View directory record Official record
Conditions
Tachycardia, Chronic Orthostatic Intolerance
Interventions
Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder
Drug · Other · Dietary Supplement + 3 more
Lead sponsor
Satish R. Raj
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

NCT01152554
View directory record Official record
Conditions
Major Depressive Disorder, MDD, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
93
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

NCT01240967
View directory record Official record
Conditions
Healthy Volunteers, Patients, Pharmacokinetics, Renal Impairment
Interventions
TC-5214
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2014 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

NCT01153347
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
79
States / cities
Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 1 Interventional

Combinations of Pharmacologic Smoking Cessation Treatments

NCT00018187
View directory record Official record
Conditions
Smoking
Interventions
Bupropion, Mecamylamine, Nicotine Patch
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
20 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

NCT01157078
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
37
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

NCT00342563
View directory record Official record
Conditions
Alcoholism
Interventions
mecamylamine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

TC-5214 as add-on the Treatment of Major Depressive Disorder

NCT00692445
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214 + citalopram, Placebo + citalopram
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Miami, Florida • Cincinnati, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214

NCT01458899
View directory record Official record
Conditions
Healthy Subjects
Interventions
TC-5214
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nicotinic Modulation of the Default Network

NCT01223404
View directory record Official record
Conditions
Magnetic Resonance Imaging, Cognition, Nicotine, Mecamylamine
Interventions
Placebo, Nicotine, Mecamylamine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Sep 4, 2026, 4:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nicotinic Modulation of the Default Network of Resting Brain Function

NCT01240616
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of the Effects of Mecamylamine and Varenicline in Schizophrenia

NCT00455650
View directory record Official record
Conditions
Cognition in Schizophrenia
Interventions
Mecamylamine, Varenicline, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 68 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence

NCT00563797
View directory record Official record
Conditions
Alcohol Dependence, Depression
Interventions
Mecamylamine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 17, 2016 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

Treatment to Quit Smoking

NCT00018161
View directory record Official record
Conditions
Smoking
Interventions
Mecamylamine, Nicotine Patch, Cigarette brand switching
Drug · Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

Nicotinic Receptor Augmentation of SSRI Antidepressants

NCT00319319
View directory record Official record
Conditions
Depressive Disorder
Interventions
Mecamylamine hydrochloride (Inversine)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 18, 2007 · Synced Sep 4, 2026, 4:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mental Ability Challenge Study in Adults With and Without HIV

NCT03244488
View directory record Official record
Conditions
HIV-1-infection, Aging, Premature, Cognitive Impairment, Memory Impairment, HIV-Associated Cognitive Motor Complex
Interventions
Scopolamine Injectable Product, Mecamylamine Pill
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
35 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 24, 2019 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 1 Interventional

Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders

NCT00773812
View directory record Official record
Conditions
Autistic Disorder, Pervasive Developmental Disorder
Interventions
mecamylamine, placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
4 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)

NCT00536692
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
mecamylamine
Drug
Lead sponsor
CoMentis
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Oakland, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2008 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days

NCT01145768
View directory record Official record
Conditions
Healthy
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Cholinergic Health After Menopause (CHAMP)

NCT04129060
View directory record Official record
Conditions
Postmenopausal Symptoms, Aging, Alzheimer Disease
Interventions
Cholinergic antagonist
Drug
Lead sponsor
University of Vermont
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Nashville, Tennessee • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 4, 2026, 4:02 PM EDT
Not listed Phase 4 Interventional

Mecamylamine for Autonomic Dysreflexia Prophylaxis

NCT03914677
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Mecamylamine Oral Tablet
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 6, 2019 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cholinergic Mechanisms of Attention in Aging

NCT04756232
View directory record Official record
Conditions
Subjective Cognitive Decline
Interventions
Mecamylamine Challenge, Placebo Comparator Challenge
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
55 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 4, 2026, 4:02 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

NCT01288079
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
TC-5214, Duloxetine, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Sep 4, 2026, 4:02 PM EDT